Xylazine test strip, for forensic and harm reduction applications

Order through Avantor/VWR: Box of 25

Product Overview

The Instanosis Xylazine Test Strip is a high-sensitivity, rapid lateral flow assay funded by the NIH and manufactured in the USA for forensic and harm reduction applications. Featuring an analytical cut-off threshold of 10 ng/mL, this standalone immunoassay strip identifies the veterinary sedative xylazine (“tranq”) in illicit drug samples with exceptional precision. Engineered for maximum sample preservation, it requires only 1/10th of the volume demanded by standard market test strips, delivering clear qualitative results within 5 minutes to support public health networks, forensic labs, and community outreach screening initiatives.

Technical Specifications & Key Data

This standalone immunoassay provides peerless diagnostic sensitivity for identifying non-opioid synthetic adulterants within complex chemical matrices:

• Target Analyte: Xylazine (commonly referred to as “tranq”).

• Analytical Limit of Detection (LOD): 10 ng/mL (highly optimized to minimize false-negative rates in highly diluted field samples).

• Micro-Volume Processing: Requires 90% less sample amount (1/10th of the volume demanded by competitor strips), ensuring critical primary forensic compounds remain intact for confirmatory laboratory testing.

• Result Readout Window: Definitive qualitative visual results in 5 minutes or less.

• Origin & Quality Benchmarks: Developed via competitive research funding allocations from the National Institutes of Health (NIH) and proudly Made in the U.S in an FDA-registered manufacturing facility under strict FDA QMSR Quality Standard.

Public Health & Epidemiological Context

Xylazine is a non-opioid alpha-2 adrenergic receptor agonist approved exclusively by the FDA for veterinary sedation. Its widespread emergence as an illicit adulterant presents profound public health challenges:

• Polysubstance Pervasiveness: Xylazine is most frequently identified in combination with illicit synthetic opioids like fentanyl, prolonging the drug’s sedative effects.

• Severe Clinical Manifestations: Chronic exposure is highly correlated with severe, necrotic skin ulcerations and abscesses that occur independently of the injection site, alongside profound bradycardia and hypotension.

• Naloxone Resistance: Because xylazine is not an opioid, its central nervous system depressant effects are completely unaffected by naloxone (Narcan). Rapid field screening tools are vital so harm reduction teams can alert communities to the necessity of supportive rescue breathing during overdose responses.

Frequently Asked Questions (FAQ)

• Q1: What is the exact analytical cut-off level for the Instanosis Xylazine test strip?

A: The technical limit of detection is precisely calibrated at 10 ng/mL. This low threshold ensures high-affinity detection of xylazine even when present in trace amounts or heavily diluted solutions.

• Q2: How does the sample amount requirement compare to other brands on the market?

A: Our advanced lateral flow technology requires less than 1/10th of the sample amount typically required by legacy testing strips, allowing forensic technicians and researchers to maximize sample preservation.

• Q3: Can naloxone (Narcan) reverse the effects of a xylazine exposure?

A: No. Xylazine is a veterinary sedative, not an opioid, meaning naloxone will not reverse its sedative or respiratory-depressing effects.

• Q4: Is this test strip developed and manufactured in the United States?

A: Yes. The Instanosis Xylazine test strip is entirely developed and manufactured in the USA, and its fundamental product design and assay optimization were developed using National Institutes of Health (NIH) funding.

• Q5: Can municipal health departments order this product through major scientific distributors?

A: Yes. In addition to direct institutional purchasing, the Instanosis Box of 25 strips can be procured through our verified product listings on primary laboratory distribution networks such as Avantor/VWR (link above Product Overview).

• Q6: Is this product intended for point-of-care patient medical diagnostics?

A: No. This product is strictly designed, labeled, and distributed for forensic investigations, harm reduction public health surveillance, and laboratory research applications only.

Data provided by The Center for Forensic Science Research & Education (CFSRE). Click to download the full report of Instanosis Product and Competitor’s Product.

Click to download the Instanosis xylazine test strip instruction